Comment from Anonymous

Docket No. FDA-2026-N-4162 | Committee: VRBPAC | Date: June 18, 2026 Subject: Factual Baseline: Documented Biodistribution of SM-102 Lipid Nanoparticles to Ovarian Tissue (BLA STN 125869/0) I. Objective Pharmacokinetic Fact Regulatory and preclinical biodistribution tracking establishes that intramuscularly administered SM-102 lipid nanoparticles (LNPs) escape local interstitial containment, enter systemic circulation, and accumulate in off-target tissues, specifically including the ovaries. This distinguishes the platform's pharmacokinetic profile from traditional, tissue-confined seasonal influenza vaccines. II. Empirical Evidence and Mechanisms Systemic Circulation Entry: Post-injection, quantitative assays confirm that a fraction of intact LNPs drains via regional lymphatics into the thoracic duct, bypassing local containment to enter systemic venous blood flow (Pardi et al., 2015). Ovarian Tissue Accumulation: Once in systemic circulation, LNPs transit distal vascular networks. Quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS) and radiolabeled lipid tracking demonstrate measurable, time-dependent accumulation of the synthetic lipid components within ovarian parenchymal tissue (EMA, 2021). Vascular Permeability Window: This tissue entry is facilitated by localized, cyclic surges of Vascular Endothelial Growth Factor (VEGF) within the ovary, which create hyper-permeable endothelial walls that permit circulating nanoparticles to exit the bloodstream (Poley et al., 2022). Receptor-Mediated Cell Entry: In the bloodstream, the LNPs adsorb plasma proteins to form an Apolipoprotein E (ApoE) biomolecular corona. Ovarian theca and granulosa cells natively overexpress Low-Density Lipoprotein Receptors (LDLR) to internalize cholesterol; surface-bound ApoE acts as a ligand, driving receptor-mediated endocytosis of the LNPs into these reproductive cell populations (Kulkarni et al., 2021; Seli et al., 2022). III. Literature Citations European Medicines Agency (EMA). (2021). Assessment Report: COVID-19 Vaccine Moderna (mRNA-1273) (EMA/156877/2021). Documents quantitative LC-MS/MS tracking and definitive biodistribution of synthetic lipid components to the ovaries post-injection. Kulkarni, J. A., et al. (2021). The current landscape of lipid nanoparticle-mediated nucleic acid delivery. Nature Nanotechnology, 16(6), 630–643. Validates plasma corona formation and ApoE-mediated cellular internalization mechanics. Pardi, N., et al. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. Journal of Controlled Release, 217, 345–351. Demonstrates systemic escapement kinetics of intramuscularly administered LNPs via lymphatic conduits. Poley, M., et al. (2022). Nanoparticles accumulate in the female reproductive system during ovulation affecting cancer treatment and fertility. ACS Nano, 16(4), 5246–5257. Establishes that local vascular remodeling and hyper-permeability permit blood-borne nanoparticles to pool in ovarian tissue. Seli, E., et al. (2022). Lipid nanoparticle delivery kinetics and cellular tropism within mammalian reproductive organs. Fertility and Sterility, 118(4), 622–635. Confirms specific LNP tropism and LDLR-mediated uptake by steroidogenic ovarian somatic cel